Skip to main content
    E

    Enveric Biosciences Inc (ENVB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.39
    +0.02 (+1.46%)

    Market Cap: $6.27M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(14/25)
    Avg Surprise
    -463.70%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 14
    		$-0.76N/AN/ABeat+93.5%
    Mar 26
    Reported May 15
    		$-1.08N/AN/ABeat+77.5%
    Dec 25
    Reported Mar 27
    		$-3.81N/AN/ABeat-87.5%
    Sep 25
    Reported Nov 14
    		$-10.81$-0.35-2988.57%Miss+75.0%
    Jun 25
    Reported Aug 14
    		$-11.65$-0.35-3228.57%Miss+74.1%
    Mar 25
    Reported May 14
    		$-4.82$-0.40-1104.20%Miss+95.6%
    Dec 24
    Reported Mar 31
    		$-2.03$-2.76+26.45%Beat-38.1%
    Sep 24
    Reported Nov 14
    		$-43.20N/A+53.85%Beat+85.0%
    Jun 24
    Reported Aug 12
    		$-45.00N/A+54.55%Beat+90.0%
    Mar 24
    Reported May 14
    		$-109.80$-139.50+21.29%Beat-2492.7%
    Dec 23
    Reported Mar 25
    		$-1.47$-1.54+4.55%Beat+99.6%
    Sep 23
    Reported Nov 13
    		$-287.12$-376.20+23.68%Beat+50.7%
    Jun 23
    Reported Aug 14
    		$-450.42$-117.00-284.97%Miss+44.9%
    Mar 23
    Reported May 15
    		$-4.24$-2.23-89.91%Miss+99.6%
    Dec 22
    Reported Mar 31
    		$-344.11$-525.60+34.53%Beat-286.6%
    Sep 22
    Reported Nov 14
    		$-582.21$-720.00+19.14%Beat+46.1%
    Jun 22
    Reported Aug 12
    		$-818.08$-675.00-21.20%Miss+54.6%
    Mar 22
    Reported May 13
    		$-990.00$-1080.00+8.33%Beat-2474900.0%
    Dec 21
    Reported Mar 31
    		$-89.00$-8.00-1012.50%Miss-222400.0%
    Sep 21
    Reported Nov 15
    		$-1080.00$-1260.00+14.29%Beat-224900.0%
    Jun 21
    Reported Aug 13
    		$-1800.00$-1575.00-14.29%Miss-4499900.0%
    Mar 21
    Reported Apr 1
    		$-0.04N/A+99.58%Beat-60.0%
    Sep 20
    Reported Nov 16
    		$-0.04N/AN/ABeat+94.7%
    Jun 20
    Reported Aug 14
    		$-0.48N/AN/ABeat+52.0%
    Mar 20
    Reported May 15
    		$-0.04N/AN/ABeat+100.0%
    Sep 19
    Reported Nov 8
    		$-0.03N/A+99.50%Beat+100.0%
    Jun 19
    Reported Aug 14
    		$-0.75N/A+99.50%Beat+99.8%
    Mar 19
    Reported May 14
    		$-1.00N/AN/ABeat+55.6%
    Dec 18
    Reported Mar 26
    		$-1600.00$-200.00-700.00%Miss-28990.9%
    Sep 18
    Reported Nov 14
    		$-300.00$-250.00-20.00%Miss-115284.6%
    Jun 18
    Reported Aug 14
    		$-300.00$-400.00+25.00%Beat-333233.3%
    Mar 18
    Reported Apr 2
    		$-2.25$-0.08-2712.50%Miss-124.0%
    Sep 17
    Reported Nov 13
    		$-5.50N/AN/ABeat-
    Jun 17
    Reported Aug 14
    		$-0.26N/AN/ABeat-
    Mar 17
    Reported May 12
    		$-0.09N/AN/ABeat-
    Dec 16
    Reported Mar 31
    		$9.37N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.08EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-170.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-7800.00x
    Current Ratio10.21xQuick Ratio10.21x
    Trading Statistics
    Beta1.18Avg Volume77.64K
    52-Week High$13.2552-Week Low$1.17

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.46
    SMA 20$1.49
    SMA 50$1.47
    SMA 200$2.16
    EMA 10$1.44
    EMA 20$1.46
    EMA 50$1.49
    EMA 200$3.00

    MACD

    Line: -0.02Signal: -0.00Hist: -0.01

    ADX

    ADX: 15.4+DI: 11.7-DI: 15.9

    Aroon & PSAR

    Aroon Up24.0
    Aroon Down96.0
    PSAR$1.48

    Bollinger Bands

    Upper Band$1.61
    Lower Band$1.36
    %B Position1657%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    41.9

    Momentum Oscillators

    Stoch %K17.8
    Stoch %D20.1
    Williams %R-73.9
    ROC (10d)-4.8%
    Momentum-0.07
    CCI (20d)-150.6
    MFI (14d)43.9

    Volatility Measures

    ATR (14d)$0.09(6.8%)
    StdDev (20d)0.06
    Hist Vol38.0%(Moderate)

    Volume Flow

    VWAP$1.39
    OBV251.0M
    AD Line11.2B
    CMF (20d)-0.018

    Volume Metrics

    Avg Vol (20d)74.2K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.49

    Pivot Points

    R3$1.56
    R2$1.50
    R1$1.44
    Pivot Point$1.38
    S1$1.32
    S2$1.26
    S3$1.20

    Advanced Oscillators

    TSI-6.62
    Ultimate Osc44.8
    KST1.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$340,376$0$0$0$647,092$0
    Cost of Revenue$36,826$37,240$39,485$40,369$39,980$81,024$82,487$84,814$84,779$85,409$84,682$95,839
    Gross Profit$-36,826$-37,240$-39,485$-40,369$-39,980$-81,024$-82,487$-84,814$-84,779$-85,409$-84,682$-95,839
    Operating Expenses$2.99M$1.60M$2.15M$1.83M$2.48M$2.11M$3.09M$2.00M$1.81M$2.39M$2.30M$3.35M
    R&D$1.36M$345,969$372,178$402,417$1.26M$746,371$1.10M$762,717$515,501$458,155$1.37M$1.35M
    SG&A$1.64M$1.25M$1.78M$1.43M$1.22M$1.36M$1.99M$1.24M$1.30M$1.93M$2.78M$2.01M
    Operating Income$-3,027,441$-1,633,170$-2,193,923$-1,873,943$-2,519,049$-2,187,533$-3,173,826$-2,083,192$-1,897,931$-2,477,320$-2,384,360$-3,448,395
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$292$303$250$274$132$0$0$217$35$696$544$2,237
    Income Before Tax$-3,027,733$-1,633,473$-2,194,171$-1,873,669$-2,519,181$-2,184,966$-3,147,447$-2,084,032$-1,879,394$-2,455,184$-3,413,618$-2,815,621
    Income Tax Expense$0$0$0$1.51M$0$0$7,199$0$1$1,731$22,318$6,595
    Net Income$-3,027,733$-1,633,473$-2,194,171$-1,873,669$-2,519,181$-2,184,966$-3,154,646$-2,084,032$-1,879,394$-2,456,915$-3,435,936$-2,822,216
    EBITDA$-2,990,615$-1,595,930$-2,154,436$-1,833,300$-2,479,199$-2,103,947$-3,064,960$-1,999,221$-1,794,610$-2,369,775$-3,328,936$-2,719,782
    EBIT$-3,027,441$-1,633,170$-2,193,921$-1,873,669$-2,519,179$-2,184,971$-3,147,447$-2,084,035$-1,879,389$-2,455,184$-3,413,618$-2,815,621
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ENVB

    News

    Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

    Enveric Biosciences announced that CEO Joseph Tucker, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Tucker will provide updates on the advancement of lead...

    The National Law Review•9/19/26•Bullish

    Enveric receives U.S. patent allowance for psychiatric compounds

    Enveric Biosciences (NASDAQ:ENVB) has received a U.S. patent allowance for compounds within its EVM401 Series, designed for psychiatric and neurological disorders. These mescaline-derived compounds are intended...

    Investing.com•9/15/26•Bullish

    Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

    Enveric Biosciences announced a new U.S. patent allowance for novel compounds in its EVM401 Series, which are non-hallucinogenic mescaline derivatives designed to promote neuroplasticity. This patent strengthens...

    Yahoo! Finance Canada•9/15/26•Bullish

    Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

    Enveric Biosciences has secured a new U.S. patent allowance for its EVM401 Series, covering novel non-hallucinogenic mescaline derivatives aimed at treating PTSD and other psychiatric disorders. This patent strengthens...

    Investing News Network•9/15/26•Bullish

    Enveric receives U.S. patent allowance for psychiatric compounds By Investing.com

    Enveric Biosciences has received a U.S. patent allowance for compounds within its EVM401 Series, which are mescaline-derived and designed to treat psychiatric and neurological disorders. This marks the third U.S. patent...

    Investing.com UK•9/15/26•Bullish

    ENVB Valuation and Fair Value

    P/E
    -0.1x
    Forward P/E
    23.1x
    P/B
    0.7x
    See GNG's fair value

    ENVB Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -170.0%
    FCF margin
    -24.2%

    ENVB Competitors

    CompanyTicker
    Co-Diagnostics, Inc. Common StockCODX
    Traws Pharma IncTRAW
    Neurosense Therapeutics LtdNRSN
    Reviva Pharmaceuticals Holdings Inc.RVPH
    Nutriband Inc. WarrantNTRBW
    Zhongchao IncZCMD
    FibroBiologics, Inc. Common StockFBLG
    Healthcare Triangle IncHCTI

    Sector: Healthcare

    ENVB Bull Case vs Bear Case

    Bear case

    • ENVB's quarterly revenue changed -7.3% year over year.

    ENVB Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    -895.1%

    Frequently Asked Questions About ENVB

    Does ENVB pay dividends?

    Enveric Biosciences Inc (ENVB) does not currently pay a regular dividend.

    What is ENVB's market cap?

    Enveric Biosciences Inc (ENVB) has a market capitalization of $6.27M with a current stock price of $1.39.

    Related stocks

    Sector: Healthcare

    All stocks starting with E

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In